Certified Advisory Corp boosted its holdings in Merck & Co., Inc. (NYSE:MRK – Free Report) by 9.9% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 6,146 shares of the company’s stock after buying an additional 554 shares during the period. Certified Advisory Corp’s holdings in Merck & Co., Inc. were worth $761,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently added to or reduced their stakes in MRK. Vermillion & White Wealth Management Group LLC acquired a new stake in Merck & Co., Inc. in the 4th quarter worth about $27,000. Burkett Financial Services LLC acquired a new stake in Merck & Co., Inc. in the 4th quarter worth about $28,000. Clear Investment Research LLC acquired a new stake in Merck & Co., Inc. in the 4th quarter worth about $39,000. Itau Unibanco Holding S.A. acquired a new stake in Merck & Co., Inc. in the 2nd quarter worth about $39,000. Finally, Roble Belko & Company Inc boosted its stake in Merck & Co., Inc. by 35.3% in the 1st quarter. Roble Belko & Company Inc now owns 326 shares of the company’s stock worth $43,000 after buying an additional 85 shares during the last quarter. 76.07% of the stock is owned by institutional investors and hedge funds.
Merck & Co., Inc. Stock Performance
Shares of NYSE:MRK opened at $115.60 on Tuesday. The company has a market cap of $292.79 billion, a P/E ratio of 128.44, a PEG ratio of 1.59 and a beta of 0.39. The company has a debt-to-equity ratio of 0.80, a quick ratio of 1.22 and a current ratio of 1.47. Merck & Co., Inc. has a one year low of $99.14 and a one year high of $134.63. The business’s 50-day simple moving average is $117.60 and its 200 day simple moving average is $124.26.
Merck & Co., Inc. Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, October 7th. Shareholders of record on Monday, September 16th will be issued a dividend of $0.77 per share. The ex-dividend date is Monday, September 16th. This represents a $3.08 annualized dividend and a yield of 2.66%. Merck & Co., Inc.’s dividend payout ratio is presently 342.22%.
Wall Street Analyst Weigh In
MRK has been the topic of a number of research analyst reports. Bank of America decreased their price target on Merck & Co., Inc. from $150.00 to $145.00 and set a “buy” rating on the stock in a research note on Wednesday, July 31st. Argus upgraded Merck & Co., Inc. to a “strong-buy” rating in a report on Wednesday, June 5th. Wolfe Research upgraded Merck & Co., Inc. to a “strong-buy” rating in a report on Wednesday, July 31st. Wells Fargo & Company cut their price objective on Merck & Co., Inc. from $140.00 to $125.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 31st. Finally, Morgan Stanley raised their price objective on Merck & Co., Inc. from $132.00 to $134.00 and gave the stock an “equal weight” rating in a report on Thursday, July 11th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, nine have issued a buy rating and four have given a strong buy rating to the stock. Based on data from MarketBeat.com, Merck & Co., Inc. presently has an average rating of “Buy” and a consensus target price of $134.58.
View Our Latest Stock Analysis on MRK
Merck & Co., Inc. Profile
Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.
See Also
- Five stocks we like better than Merck & Co., Inc.
- What is an Earnings Surprise?
- The Average 401k Balance by Age Explained
- What is the Dogs of the Dow Strategy? Overview and Examples
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.